{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:07:04Z","timestamp":1780409224009,"version":"3.54.1"},"reference-count":84,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background\/Objectives: Developing antifungal drugs with lower potential for interactions with food may help to optimize treatment and reduce the risk of antimicrobial resistance. Chemometrics uses statistical and mathematical methods to analyze multivariate chemical data, enabling the identification of key correlations and simplifying data interpretation. We used the partial least squares (PLS) approach to explore the correlations between various characteristics of oral antifungal drugs (including antifungal antibiotics) and dietary interventions, aiming to identify patterns that could inform the optimization of antifungal therapy. Methods: We analyzed 15 oral antifungal drugs, including azoles (8), antifungal antibiotics (4), antifungal antimetabolites (1), squalene epoxidase inhibitors (1), and glucan synthase inhibitors (1). The input dataset comprised information from published clinical trials, chemical records, and calculations. We constructed PLS models with changes in the pharmacokinetic parameters (\u2206AUC, area under the curve; \u2206Cmax, maximum drug concentration; and \u2206Tmax, time to reach maximum drug concentration) after dietary intervention as the response parameters and eight groups of molecular descriptors (M1\u2013M8) as the predictor parameters. We performed separate analyses for the different nutritional interventions. Results: In the final PLS model with food as an intervention, we effectively reduced the dimensionality of the dataset while retaining a substantial percentage of the original information (variance), as significant components explained 69.8% and 17.5% of the predictor and response parameter variances, respectively. The PLS model was significant because its components met the cross-validation criteria. We obtained six significant positive and negative correlations between the descriptors related to atoms and the postprandial \u2206Tmax. Conclusions: The PLS method is valuable for investigating interactions between antifungal drugs (including antifungal antibiotics) and food. The correlations obtained can be used in drug modeling to predict interactions with dietary interventions based on the antifungal drug\u2019s chemical structure. Incorporating chemometric techniques into the early drug development stages could facilitate the design of antifungal antibiotics and other antifungal agents with optimized absorption in the presence of dietary components.<\/jats:p>","DOI":"10.3390\/antibiotics14010070","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T09:24:42Z","timestamp":1736501082000},"page":"70","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemometric Methods\u2014A Valuable Tool for Investigating the Interactions Between Antifungal Drugs (Including Antifungal Antibiotics) and Food"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4926-6120","authenticated-orcid":false,"given":"Agnieszka","family":"Wiesner-Kie\u0142czewska","sequence":"first","affiliation":[{"name":"Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 31-008 Cracow, Poland"},{"name":"Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 31-008 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-036X","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zagrodzki","sequence":"additional","affiliation":[{"name":"Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 31-008 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-9300","authenticated-orcid":false,"given":"Alicja","family":"Gawalska","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 31-008 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-4492","authenticated-orcid":false,"given":"Pawe\u0142","family":"Pa\u015bko","sequence":"additional","affiliation":[{"name":"Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 31-008 Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"EClinicalMedicine (2021). Antimicrobial resistance: A top ten global public health threat. eClinicalMedicine, 41, 101221.","DOI":"10.1016\/j.eclinm.2021.101221"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aap7999","article-title":"Worldwide emergence of resistance to antifungal drugs challenges human health and food security","volume":"360","author":"Fisher","year":"2018","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e02127-23","DOI":"10.1128\/spectrum.02127-23","article-title":"Evolutionary trends in antifungal resistance: A meta-analysis","volume":"12","author":"Niu","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.idc.2021.03.003","article-title":"Resistance to Antifungal Drugs","volume":"35","author":"Kontoyiannis","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(24)01695-7","article-title":"Beyond bacteria: The growing threat of antifungal resistance","volume":"404","author":"Beardsley","year":"2024","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/MCC.0000000000000758","article-title":"Adequate duration of therapy in severe fungal infections","volume":"26","author":"Bassetti","year":"2020","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"ofac656","DOI":"10.1093\/ofid\/ofac656","article-title":"Short course of antifungal therapy in patients with uncomplicated Candida bloodstream infection: Another case of less is more in the clinical setting?","volume":"10","author":"Vena","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Vitiello, A., Ferrara, F., Boccellino, M., Ponzo, A., Cimmino, C., Comberiati, E., Zovi, A., Clemente, S., and Sabbatucci, M. (2023). Antifungal Drug Resistance: An Emergent Health Threat. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041063"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3476(83)80549-6","article-title":"Clinical and laboratory observations. Effect of feeding on bioavailability of griseofulvin in children","volume":"102","author":"Ginsburg","year":"1983","journal-title":"J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002280050280","article-title":"Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole","volume":"52","author":"Jaruratanasirikul","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/j.1552-4604.1997.tb04332.x","article-title":"Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers","volume":"37","author":"Lange","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1128\/AAC.39.8.1671","article-title":"Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole: Monitoring of intraluminal and plasma drug concentrations","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_15","first-page":"306","article-title":"Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects","volume":"36","author":"Kawakami","year":"1998","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2710.2005.00632.x","article-title":"Reduced oral itraconazole bioavailability by antacid suspension","volume":"30","author":"Lohitnavy","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.21.1.151","article-title":"Disposition of ketoconazole, an oral antifungal, in humans","volume":"21","author":"Brass","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":"Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers","volume":"50","author":"Krishna","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s10461-022-03880-6","article-title":"Interactions of antiretroviral drugs with food, beverages, dietary supplements, and alcohol: A systematic review and meta-analyses","volume":"27","author":"Wiesner","year":"2023","journal-title":"AIDS Behav."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: Transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s11095-007-9236-1","article-title":"Predicting effect of food on extent of drug absorption based on physicochemical properties","volume":"24","author":"Gu","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/bcp.15796","article-title":"Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food","volume":"89","author":"Wiesner","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1007\/s00216-017-0517-1","article-title":"Chemometrics in analytical chemistry\u2014Part I: History, experimental design and data analysis tools","volume":"409","author":"Brereton","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_25","first-page":"549","article-title":"Partial least squares methods: Partial least squares correlation and partial least square regression","volume":"Volume 27","author":"Abdi","year":"2013","journal-title":"Alternatives to Laboratory Animals: ATLA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2015.12.006","article-title":"Chemometric analysis of the interactions among different parameters describing health conditions, breast cancer risk and fatty acids profile in serum of rats supplemented with conjugated linoleic acids","volume":"106","author":"Zagrodzki","year":"2016","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_27","unstructured":"Naumann, K. (2003). How Chlorine in Molecules Affects Biological Activity, Euro Chlor."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.funbio.2017.08.002","article-title":"Lipid components of bile increase the protective effect of conjugated bile salts against antifungal drugs","volume":"121","author":"Hsieh","year":"2017","journal-title":"Fungal Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hsieh, S.H., Brunke, S., and Brock, M. (2017). Encapsulation of antifungals in micelles protects Candida albicans during gall-bladder infection. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00117"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1038\/s41467-021-25091-8","article-title":"Real space electron delocalization, resonance, and aromaticity in chemistry","volume":"12","author":"Reuter","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/2472555219859845","article-title":"Using Physicochemical Measurements to Influence Better Compound Design","volume":"24","author":"Bunally","year":"2019","journal-title":"SLAS Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1039\/D0RA09995C","article-title":"The importance of intramolecular hydrogen bonds on the translocation of the small drug piracetam through a lipid bilayer","volume":"11","author":"Coimbra","year":"2020","journal-title":"RSC Adv."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jddst.2017.04.017","article-title":"Oral amphotericin B: The journey from bench to market","volume":"42","author":"Serrano","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114969","DOI":"10.1016\/j.addr.2023.114969","article-title":"Reviving the interest in the versatile drug nystatin: A multitude of strategies to increase its potential as an effective and safe antifungal agent","volume":"199","author":"Sousa","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Viecceli, C., Mattos, A.C.V., Costa, M.C.B., de Melo, R.B., Rodrigues, T.d.C., and Czepielewski, M.A. (2022). Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1017331"},{"key":"ref_37","unstructured":"FDA (2025, January 06). FDA Drug Safety Communication: FDA Warns that Prescribing of Nizoral (Ketoconazole) Oral Tablets for Unapproved Uses Including Skin and Nail Infections Continues; Linked to Patient Death, Available online: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500597.htm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_39","unstructured":"Higgins, J.P.T., Li, T., and Sterne, J.A.C. (2021). Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): Additional considerations for cross-over trials. Cochrane Methods, 1\u20136."},{"key":"ref_40","unstructured":"(2024, November 26). NIH Study Quality Assessment Tools, Available online: https:\/\/www.nihlibrary.nih.gov\/services\/systematic-review-service\/tools-resources."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/bioinformatics\/btt105","article-title":"ChemoPy: Freely available python package for computational biology and chemoinformatics","volume":"29","author":"Cao","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/jcc.21707","article-title":"PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints","volume":"32","author":"Yap","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_44","unstructured":"Schr\u00f6dinger Inc (2021). Qikprop, v11.15.0, Schr\u00f6dinger, LLC."},{"key":"ref_45","unstructured":"(2024, October 25). RDKit: Open-Source Cheminformatics. Available online: https:\/\/www.rdkit.org."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cpdd.1248","article-title":"Pharmacokinetics and Bioequivalence of Fluconazole Capsules Manufactured in France and China in Healthy Chinese Participants: Open-Label, Randomized, Single-Dose, 2-Way, Cross-over Bioequivalence Study Under Fasted and Fed Conditions","volume":"12","author":"Chen","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_47","first-page":"910","article-title":"Bioequivalence of fluconazole capsules in healthy Chinese subjects","volume":"25","author":"Li","year":"2020","journal-title":"Chin. J. Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00199879","article-title":"Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole","volume":"46","author":"Zimmermann","year":"1994","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejps.2008.07.002","article-title":"Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: A single-dose, randomized, open-label, six-period, cross-over study in healthy adult volunteers in the fasted and fed states","volume":"35","author":"Ahmed","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1248\/bpb1978.5.120","article-title":"Effect of food on the bioavailability of griseofulvin from microsize and PEG ultramicrosize (GRIS-PEG) plain tablets","volume":"5","author":"Aoyagi","year":"1982","journal-title":"J. Pharmacobiodyn."},{"key":"ref_51","unstructured":"(2024, August 12). Brexafemme (Scynexis), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214900s002lbl.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.5414\/CP202434","article-title":"Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH","volume":"54","author":"Desai","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/AAC.37.4.778","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers","volume":"37","author":"Barone","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/j.1875-9114.1998.tb03856.x","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone","year":"1998","journal-title":"Pharmacotherapy"},{"key":"ref_56","unstructured":"(2024, August 11). Medicines and Healthcare Products Regulatory Agency HGN007 Study\u2014A Single-Dose, Four-Way Cross-Over, Relative Bioavailability Study to Compare the Pharmacokinetics of the Test Product Lozanoc 50 mg Hard Capsules versus the Reference Product Sporanox 100 mg Capsules in Healthy Adult Volunteers Under Fed and Fasted Conditions. Available online: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/c86c25a27a87210e71b30f469ae86a729f4cb575."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-5173(01)00867-5","article-title":"Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability","volume":"229","author":"Kapsi","year":"2001","journal-title":"Int. J. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/ofid\/ofy210.1185","article-title":"Novel formulation suba-itraconazole in fed and fasted healthy volunteers: Expanding the clinical utility of the established mold active agent","volume":"5","author":"Lindsay","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_59","unstructured":"(2024, August 11). Center for Drug Evaluation and Research MPG017 Study\u2014TOLSURA Capsules 130 mg [2 \u00d7 65 mg] Administered Under Fed and Fasted Conditions in 24 Healthy Volunteers; 2018, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208901Orig1s000MultidisciplineR.pdf."},{"key":"ref_60","unstructured":"(2024, August 12). Tradename (Sanico), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022484s000lbl.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.11150\/kansenshogakuzasshi.83.369","article-title":"Influence of black vinegar on itraconazole absorption","volume":"83","author":"Oguma","year":"2009","journal-title":"Kansenshogaku Zasshi."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0013421","DOI":"10.1128\/AAC.00134-21","article-title":"Bioavailability of Single-Dose SUBA-Itraconazole Compared to Conventional Itraconazole under Fasted and Fed Conditions","volume":"65","author":"Rauseo","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","first-page":"6","article-title":"Single- and multiple-dose pharmacokinetics of intraconazole oral solution in healthy men","volume":"54","author":"Tei","year":"2006","journal-title":"Jpn. J. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","article-title":"Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole","volume":"16","author":"Heykants","year":"1996","journal-title":"Pharmacotherapy"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Woestenborghs","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2007.11.001","article-title":"Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers","volume":"33","author":"Woo","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00228-006-0200-5","article-title":"Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers","volume":"62","author":"Yun","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.25.1.1","article-title":"Influence of food on the pharmacokinetics of ketoconazole","volume":"25","author":"Daneshmend","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.21.5.730","article-title":"Impairing effect of food on ketoconazole absorption","volume":"21","author":"Lamminsivu","year":"1982","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","unstructured":"(2024, August 12). Vivjoa (Mycovia Pharmaceuticals), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000lbl.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.36519\/idcm.2023.277","article-title":"Single-Dose Cross-over Comparative Bioavailability Study of Two Different Posaconazole 100 mg Gastro-Resistant Tablets Under Fasted and Fed Conditions in Healthy Volunteers","volume":"5","author":"Dayan","year":"2023","journal-title":"Infect. Dis. Clin. Microbiol."},{"key":"ref_73","first-page":"S42","article-title":"The effect of food on the posaconazole pharmacokinetics investigated during the development of a new tablet formulation","volume":"95","author":"Dogterom","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.xphs.2016.03.027","article-title":"Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion","volume":"105","author":"Hens","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1128\/AAC.05000-14","article-title":"Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40261-019-00833-1","article-title":"Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability","volume":"39","author":"Li","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FTD.0b013e3182818a56","article-title":"A randomized, phase I, 3-way cross-over study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects","volume":"35","author":"Lin","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"ref_80","unstructured":"Noxafil (Merck & Co.) (2024, August 12). Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205053s1lbl.pdf."},{"key":"ref_81","first-page":"173","article-title":"Liquid chromatography-mass spectrometry method for the quantification of posaconazole in human plasma: Application to pharmacokinetics following single-dose administration in the fasted state and with a high-fat meal","volume":"68","author":"Xu","year":"2013","journal-title":"Pharmazie"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1099-081X(199703)18:2<127::AID-BDD6>3.0.CO;2-8","article-title":"The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects","volume":"18","author":"Nedelman","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_83","unstructured":"(2024, August 12). Vfend (Pfizer), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021266s039,021267s050,021630s029lbl.pdf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/1\/70\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:26:35Z","timestamp":1759919195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/1\/70"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["antibiotics14010070"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14010070","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]}}}